NCT00734188View on ClinicalTrials.gov

Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

June 30, 2010

Conditions

Metastatic Melanoma

Interventions

DRUG

PTI-6D2

monoclonal antibody

Trial Locations (1)

Unknown

Hadassah Hebrew University Hospital, Jerusalem

Sponsors

Lead Sponsor

Pain Therapeutics

All Listed Sponsors

lead

Pain Therapeutics

INDUSTRY

NCT00734188 - Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter